Can Bee Venom Peptide Melittin Treat Chemotherapy-Induced Nerve Damage?

This is a hybrid publication combining a narrative review of existing research on melittin for CIPN with an original laboratory finding. The review synthesizes preclinical evidence for melittin's neuroprotective effects. The original component demonstrates that α-Crystallin protein can inhibit melittin-induced hemolysis in vitro, presenting a potential strategy for overcoming melittin's key safety limitation.

Chemotherapy-induced peripheral neuropathy affects up to 38% of patients on multi-drug regimens, causing pain, numbness, and motor dysfunction that can persist long after treatment ends. Current options — opioids, NSAIDs, and antidepressants — offer only short-term symptom relief with their own side effects. Melittin could fill this therapeutic gap if its toxicity problem is solved, and the α-Crystallin discovery offers a concrete path forward.

CIPN remains one of the most common and undertreated complications of cancer treatment. The search for effective therapies has stalled because most candidates only address symptoms. Venom-derived peptides like melittin represent a different approach — targeting the underlying nerve damage rather than just the pain. If the toxicity hurdle can be cleared with strategies like α-Crystallin co-administration, melittin could become the first curative therapy for a condition affecting millions of cancer survivors.

This is primarily a review article, not a clinical trial. The α-Crystallin finding is preliminary and needs extensive validation in animal models and eventually human studies. No human clinical trials of melittin for CIPN have been conducted. The feasibility of combining melittin with α-Crystallin for therapeutic use — including dosing, delivery, and pharmacokinetics — remains unexplored.